Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 04, 2013 08:30 ET | Source: Immunomedics, Inc.

Immunomedics to Present at Stifel Healthcare Conference 2013

MORRIS PLAINS, N.J., Sept. 4, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
September 03, 2013 16:00 ET | Source: Immunomedics, Inc.

Immunomedics Appoints Peter P. Pfreundschuh as New Chief Financial Officer

MORRIS PLAINS, N.J., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
August 22, 2013 16:00 ET | Source: Immunomedics, Inc.

Immunomedics Announces Fiscal 2013 Results

MORRIS PLAINS, N.J., Aug. 22, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
August 20, 2013 14:05 ET | Source: Immunomedics, Inc.

Immunomedics Appoints Richard L. Sherman to Board of Directors

MORRIS PLAINS, N.J., Aug. 20, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
August 14, 2013 08:30 ET | Source: Immunomedics, Inc.

Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma

-- 88.2% Overall Response Rate, Including 42.4% Complete Responses -- -- 60% of Patients Remain in Remission at 3 Years Follow-Up -- MORRIS PLAINS, N.J., Aug. 14, 2013 (GLOBE NEWSWIRE) --...
August 12, 2013 08:30 ET | Source: Immunomedics, Inc.

Immunomedics Advances Solid Tumor Antibody-Drug Conjugate Programs to Phase II Clinical Trials

MORRIS PLAINS, N.J., Aug. 12, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
August 09, 2013 08:30 ET | Source: Immunomedics, Inc.

Immunomedics Announces Conference Call and Webcast for Fourth Quarter and Fiscal Year 2013 Financial Results

MORRIS PLAINS, N.J., Aug. 9, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
July 16, 2013 08:30 ET | Source: Immunomedics, Inc.

Immunomedics Constructs New Humanized Antibody for B-Cell Mediated Cancer and Autoimmune Diseases

MORRIS PLAINS, N.J., July 16, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU),a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...
July 03, 2013 09:15 ET | Source: Immunomedics, Inc.

Immunomedics Reports First Results From Phase Ib Study of 90Y-Clivatuzumab in Patients With Metastatic Pancreatic Cancer After 2 or More Prior Therapies

-- Repeated Cycles of 90Y-Clivatuzumab Treatments Extended Survival When Compared to Single Cycle -- -- Low-Dose Gemcitabine in Combination with 90Y-Clivatuzumab Significantly Improved...
June 14, 2013 08:30 ET | Source: Immunomedics, Inc.

Immunomedics to Present at Wells Fargo Securities 2013 Healthcare Conference

MORRIS PLAINS, N.J., June 14, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the...